N-acetonyl-4-methylbenzamide | 848186-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-acetonyl-4-methylbenzamide
• 英文别名: 1-(p-toluoylamino)-2-propanone；4-methyl-N-(2-oxopropyl)benzamide
• CAS: 848186-86-7
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: MVNJWFVAYSIJFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-acetonyl-4-methylbenzamide 、 ethyl 6-iodohexanoate 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 7-acetyl-7-(p-toluoylamino)heptanoate
  参考文献：
  名称：

  Heterocyclic compounds

  摘要：

  本发明提供了一种用于高脂血症的预防或治疗剂，其活性成分为式[1]所示的杂环化合物或其药学上可接受的盐：R1-Het-D-E [1]其中：R1为任选取代的芳基或芳香性杂环基团，Het为二价芳香性杂环基团，D为亚烷基、亚烯基、亚炔基等，E为羧基等，以及上述式[1]所示杂环化合物中的新型化合物，其具有降低血液甘油三酯、降低LDL-C、降低血糖、降低血液胰岛素、增加HDL-C或降低动脉粥样硬化指数的效果，因此可用于预防或治疗高脂血症、动脉硬化、糖尿病、高血压、肥胖等疾病。

  公开号：

  US20030166697A1
• 作为产物：
  描述：

  N-(2-hydroxypropyl)-4-methylbenzamide 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以71%的产率得到N-acetonyl-4-methylbenzamide
  参考文献：
  名称：

  Structure–activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists

  摘要：

  A series of 1,3-dioxane carboxylic acid derivatives was synthesized and evaluated for human PPAR transactivation activity. Structure-activity relationships on the phenyloxazole moiety of the lead compound 3 revealed that the introduction of small hydrophobic substituents at the 4-position of the terminal phenyl ring increased the PPAR alpha agonist activity, and that the oxazole heterocycle was essential to the maintenance of both potency and PPAR alpha subtype-selectivity. This investigation led to the identification of 14d (NS-220) and 14i as highly potent and selective human PPAR alpha agonists. In KK-A(y) type 2 diabetic mice, these compounds significantly lowered plasma triglyceride and very-low-density plus low-density lipoprotein cholesterol levels while simultaneously raising HDL cholesterol levels. Our results suggest that highly potent and subtype-selective PPAR alpha agonists will be promising drugs for the treatment of metabolic disorders in type 2 diabetes. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.007

文献信息

• [EN] NOVEL DIOL COMPOUNDS SYNTHESIS AND ITS USE FOR FORMAL SYNTHESIS OF (2R, 3 S)-3-HYDROXYPIPECOLIC ACID<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE NOUVEAUX COMPOSÉS DE DIOL ET SON UTILISATION POUR LA SYNTHÈSE FORMELLE D'ACIDE (2R, 3S)-3-HYDROXYPIPÉCOLIQUE
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2016056031A1

  公开（公告）日：2016-04-14

  The patent discloses novel diol derivatives of general formula I, [Formula should be inserted here] A chiral pool process for the synthesis of the compound of formula I from D glucose. Further, it discloses a process for the synthesis of (2R, 3S)-3-hydroxypipecolic acid from D- glucose using chiral pool approach, wherein the D-glucose used is in enantiomerically pure form.

  该专利披露了一种通式I的新型二醇衍生物，[此处应插入公式] 从D-葡萄糖开始合成公式I化合物的手性池方法。此外，它还披露了一种从D-葡萄糖使用手性池方法合成(2R,3S)-3-羟基哌酸的过程，其中使用的D-葡萄糖为对映纯形式。
• CRYSTAL OF HETEROCYCLIC COMPOUND
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1666479A1

  公开（公告）日：2006-06-07

  The main purpose of the invention is to provide a new specific crystal of 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-r-2-carboxylic acid. The invention includes, for example, a crystal of 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-r-2-carboxylic acid, which has peaks at the angles of diffraction of at least 12.4°, 17.1°, and 20.8° in a powder X-ray diffraction spectrum, and a preventive or therapeutic agent comprising the crystal as an active ingredient for use in coronary artery diseases, cerebral infarction, hyperlipemia, arteriosclerosis, diabetes mellitus, hypertension, or obesity.

  该发明的主要目的是提供一种2-甲基-C-5-[4-[5-甲基-2-(4-甲基苯基)-1,3-噁唑-4-基]丁基]-1,3-二噁烷-R-2-羧酸的新晶体。该发明包括2-甲基-C-5-[4-[5-甲基-2-(4-甲基苯基)-1,3-噁唑-4-基]丁基]-1,3-二噁烷-R-2-羧酸的晶体，其在粉末X射线衍射谱中具有至少12.4°、17.1°和20.8°的衍射角峰，并且包括该晶体作为活性成分的预防或治疗剂，用于冠状动脉疾病、脑梗塞、高脂血症、动脉硬化、糖尿病、高血压或肥胖症。
• HETEROCYCLIC COMPOUNDS
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1295875A1

  公开（公告）日：2003-03-26

  The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1] or a pharmaceutically acceptable salt thereof:         R1―Het―D―E     [1] wherein: R1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

  本发明提供了一种预防或治疗高脂血症的药物，其活性成分包括式 [1] 的杂环化合物或其药学上可接受的盐： R1-Het-D-E [1] 其中 R1为任选取代的芳基或芳香杂环基团，Het为二价芳香杂环基团，D为亚烷基、亚烯基、亚炔基或类似基团，E为羧基或类似基团，上述式[1]杂环化合物中的新型化合物，具有降血甘油三酯作用、低密度脂蛋白胆固醇（LDL-C）降低效果、血糖降低效果和血胰岛素降低效果，或高密度脂蛋白胆固醇（HDL-C）增加效果或动脉粥样硬化指数降低效果，因此可用于预防或治疗高脂血症、动脉硬化、糖尿病、高血压、肥胖症等。
• Heterocyclic compounds for the treatment of hyperlipidemia agents
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1634876A2

  公开（公告）日：2006-03-15

  The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1] or a pharmaceutically acceptable salt thereof:         R 1 -Het-D-E     [1] The preventive or therapeutic agent has a blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

  本发明提供了一种预防或治疗高脂血症的药物，其活性成分包括式 [1] 的杂环化合物或其药学上可接受的盐： R 1 -Het-D-E [1] 该预防或治疗剂具有降血甘油三酯作用、降低密度脂蛋白胆固醇作用、降血糖作用和降血胰岛素作用，或增加高密度脂蛋白胆固醇作用或降低动脉粥样硬化指数作用，因此可用于预防或治疗高脂血症、动脉硬化、糖尿病、高血压、肥胖症等。
• PROTEASE DETECTION
  申请人：Mologic Ltd

  公开号：EP2222404B1

  公开（公告）日：2018-08-01